RxDoctor Payments Data

Ahsan Rashid, MD

Internal Medicine · Irvine, CANPI 1588764047

Payments from drug & device makers

$465in general payments, 2019–2025

Across 17 payments — averaging $27.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$233
  • Amgen$66
  • Boston Scientific$33
  • Boehringer Ingelheim$31
  • Abbott$27
  • CMP Pharma, Inc.$25
  • plus $50 from 3 others

What the payments were for

  • Food & beverage$465100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$465 in reported general payments places this provider in the 65th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$165,490
Medicare patients
177
Services billed
2,189

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide89$98,335
EliquisApixaban118$94,667
CreonLipase/Protease/Amylase26$54,763
JanuviaSitagliptin Phosphate42$44,747
MounjaroTirzepatide29$41,321
JardianceEmpagliflozin22$31,146
XareltoRivaroxaban24$16,669
JanumetSitagliptin Phos/Metformin Hcl16$12,284
MyrbetriqMirabegron15$11,858
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$11,637
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$9,115
Memantine Hcl ErMemantine Hcl25$4,783
Humalog Kwikpen U-100Insulin Lispro11$4,175
BrilintaTicagrelor18$4,004
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$3,832

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$233$94,667118 claims
Lilly USA, LLCMounjaro$16$41,32129 claims
Boehringer IngelheimJardiance$31$31,14622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Irvine

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →